Concepedia

Publication | Open Access

BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial

DOIFull Paper Access

89

Citations

22

References

2021

Year

Eric Lawitz, Diane E. Shevell, Giridhar Tirucherai, Shuyan Du, Warner Chen, Uma Kavita, Angie Coste, Fred Poordad, M.A. Karsdal, Mette Juul Nielsen,
Hepatology

Abstract

In patients with HCV-SVR, BMS-986263 administration was generally well tolerated through Week 36 and resulted in METAVIR and Ishak score improvements. Further evaluation of BMS-986263 in patients with active fibrogenesis is warranted.

References

YearCitations

Page 1